Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)

Fernández, Óscar; Durán, Eduardo; Ayuso, T.; Hernández, Luis; Bonaventura, I; Forner, Mireia

doi:10.1371/journal.pone.0185766

Cited by 21 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Satisfaction with injectable administration was also significantly higher in adherent patients, supporting the levels of adherence observed. It is known that the main reasons for lack of satisfaction are treatment inconvenience (needing regular injections can affect acceptance of treatment), injection burden of IV, injectable DMTs, and injection site reactions 33,34. In this context, our patients who received medication with IV administration showed a statistically higher concern for these possible mild side effects; this was primarily true for young people and women, who also showed higher levels of compliance.…”

Section: Discussionmentioning

confidence: 77%

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain

Verdugo¹,

Herráiz²,

Olmo

et al. 2019

PPA

View full text Add to dashboard Cite

Purpose Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects of treatment for multiple sclerosis (MS). There are numerous treatments that have been approved. Treatment selection is essential in patient adherence. In addition, patient preference plays an increasingly significant role in treatment decision-making. This study aims to evaluate the degree of adherence, along with other variables that may influence this adherence, in Spain. Methods A cross-sectional study was conducted with 157 MS patients with disease-modifying treatments. Adherence was assessed using the Morisky Green scale, and other related factors were measured using a questionnaire that addressed demographics, disease characteristics, global perception of pathology, impact of medication on patient’s life, and treatment decision-making. Results The adherence rate was 71% and was associated with the following variables: older age, more treatments received, time to diagnosis 5–10 years, absence of exacerbations, better cognitive status, being married/in a union, clear information about the disease, and higher treatment satisfaction. The main cause for non-compliance was forgetfulness (27%). Conclusion The adherence rate is acceptable. It is widely known that treatment satisfaction is related to adherence. In our study, patients’ level of satisfaction was higher with oral treatments. However, oral administration showed a greater lack of adherence. The main cause of lack of adherence was forgetfulness. In relation to other variables, cognitive status and family support showed a correlation with treatment adherence.

show abstract

Section: Discussionmentioning

confidence: 77%

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain

Verdugo¹,

Herráiz²,

Olmo

et al. 2019

PPA

View full text Add to dashboard Cite

show abstract

“…Scores range from 0 (normal) to 8(bed-ridden) [15]. It is a valid patient-reported outcome of disability in MS [19]. Moreover, the study questionnaire included participants' socio-demographic data, including gender, age, level of education, region, and marital status of the participants.…”

Section: Methodsmentioning

confidence: 99%

Treatment satisfaction and adherence to medications among multiple sclerosis patients in Saudi Arabia

Alhazzani

Alqahtani

Alamri

et al. 2019

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background: Despite the apparent benefits of disease-modifying drug (DMD) use among multiple sclerosis (MS) patients, their rates of adherence are often variable and in some cases are quite low. Aim of the study: To assess medication adherence and its relationship with treatment satisfaction of MS patients in Saudi Arabia Patients and methods: Following a cross-sectional design, 598 adult MS patients were recruited from all tertiary care hospitals in all regions of Saudi Arabia. Patients' medication adherence was assessed using the Arabic version of the eight-item Morisky Medication Adherence Scale (MMAS-8). Treatment satisfaction was assessed using the Treatment Satisfaction Questionnaire for Medication. Disease severity was assessed using the Patient-Determined Disease Steps (PDDS). Results: The most used drug was interferon beta-1b (24.1%), while 18.7% were using interferon beta-1a and 17.4% were using fingolimod. Patients' mean PDDS was 2.8 ± 1.9. Only 9.7% were "adherent" to medication. Patients' adherence differed according to their educational level (p < 0.001), their currently received medications (p = 0.032), with those on Fingolimod having the highest adherence (17.3%). Treatment satisfaction was significantly higher among adherent patients (p < 0.023). The main reasons for changing prescribed drugs were the presence of attacks, i.e., response to treatment was substandard (41.8%) and the experienced side effects of used drugs (39.9%). PDDS differed significantly according to patients' treatment adherence only among those receiving interferon beta-1b, with higher mean severity score among those who were adherent (p = 0.002). Conclusions: Medication adherence among MS patients in Saudi Arabia is low. Higher adherence is associated with patients' higher education. The main underlying reasons for changing prescribed drugs are the presence of attacks, substandard response to treatment, or suffering the DMDs' side effects. Medication adherence is associated with higher treatment satisfaction.

show abstract

“…In the past decade, several papers have reported on MS patient treatment satisfaction with DMT in various countries. [14][15][16][17][18][19][20] Since a patient's treatment experience is to a certain extent influenced by the local availability of particular drugs, country-specific data are needed. To the best of our knowledge, the study presented here is the first report dealing with treatment satisfaction in the Slovak MS population.…”

Section: Discussionmentioning

confidence: 99%

“…A recently published study on treatment satisfaction with injectable DMT in Spain 19 reported an effectiveness score of 66.8, convenience 72.5 and global satisfaction 68.8. These scores for convenience and global satisfaction are slightly higher than in the SKARLET study (convenience 66.9, global satisfaction 63.8), but this is in line with our assumptions on country-specific differences.…”

Section: Discussionmentioning

confidence: 99%

Real-World Treatment Patterns of Disease Modifying Therapy (DMT) for Patients with Relapse-Remitting Multiple Sclerosis and Patient Satisfaction with Therapy: Results of the Non-Interventional SKARLET Study in Slovakia

Turčãni

Mašková²,

J³

2020

PPA

View full text Add to dashboard Cite

Background: During long-term multiple sclerosis therapy, patient satisfaction with received treatment has considerable impact on treatment outcomes. Here we report the results of a non-interventional real-world study that mapped the treatment patterns of disease-modifying therapy (DMT) and assessed treatment satisfaction with DMT. Patients and Methods: The SKARLET study was a non-interventional, cross-sectional study in Slovakia running from May 2016 to March 2017. Patients with relapsing-remitting multiple sclerosis on DMT for ≥3 months and ≤2 years (per local labelling) from 10 multiple sclerosis centers across Slovakia were included. The primary objective was to collect the Treatment Satisfaction Questionnaire for Medication version 9 (TSQM 9) score regarding perceived effectiveness, convenience and overall satisfaction with DMT. Results: The following TSQM 9 scores (mean; 95% confidence interval) were reported from 415 patients: convenience (75.05; 73.49-76.61), effectiveness (68.15; 66.56-69.75) and global satisfaction scale (66.94; 65.26-68.62). All three parameters of the TSQM 9 were analyzed by the route of DMT administration, with infusions best rated for effectiveness and global satisfaction in comparison to oral dosage and injections. For convenience, however, oral dosage forms were appraised highly (82.66; 80.59-84.73) followed by infusions (74.40; 70.12-78.69), while injections were rated as the worst (66.92; 64.81-69.04). The difference of TSQM 9 scores according to the route of DMT administration is statistically significant for convenience (p < 0.001) and global satisfaction (p = 0.004), but not for effectiveness (p = 0.185). Conclusion: In the present study, it was confirmed that patients find oral DMTs as most convenient; however, the infusion form of treatment outweighs oral DMTs in global satisfaction and effectiveness. The differences of TSQM 9 scores among DMT dosage forms were significant for convenience and global satisfaction. In conclusion, the results of this detailed survey increase our understanding of RRMS patient population characteristics and patient satisfaction with DMT treatment.

show abstract

Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)

Cited by 21 publications

References 26 publications

<p>Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain</p>

<p>Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain</p>

Treatment satisfaction and adherence to medications among multiple sclerosis patients in Saudi Arabia

<p>Real-World Treatment Patterns of Disease Modifying Therapy (DMT) for Patients with Relapse-Remitting Multiple Sclerosis and Patient Satisfaction with Therapy: Results of the Non-Interventional SKARLET Study in Slovakia</p>

Contact Info

Product

Resources

About